To view or add a comment, sign in More Relevant Posts FDA Aligns With OKYOs NEPTUNE Phase 3 Trial of Urcosimod for Neuropathic Corneal Pain The U.S
Heres a clear breakdown of its proposed benefits: 1
Get medical attention if symptoms appear
The remaining 35 states (Alabama, Alaska, Arkansas, Colorado, Connecticut, Delaware, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Oregon, Rhode Island, South Carolina, South Dakota, Utah, Vermont, West Virginia, Wisconsin, Wyoming) follow their state PDL more closely with fewer MCO carve-outs
Lodewyckx P, Issa J, Gaschignard M, et al
This overview also identifies critical knowledge gaps and emerging preventive strategies (28)